Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Requirements
  • ‘Skinny Labeling’
  • Gun Control
  • Suicide Prevention
  • Rural Health Payout

TRENDING TOPICS:

  • Medicaid Work Requirements
  • 'Skinny Labeling'
  • Gun Control
  • Suicide Prevention
  • Rural Health Payout

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Tuesday, Aug 21 2018

Full Issue

Marketplace Roundup: Biotech Organogenesis To Go Public Again; Eyes On Esperion Cholesterol Trial

Health care companies Organogenesis, Esperion Therapeutics, Blue Cross and Blue Shield of Minnesota, and AbbVie make headlines today.

Boston Globe: Organogenesis Will Become A Public Company Again

Organogenesis Inc., a Canton biotech that sells wound care and skin graft products, is going public again, 16 years after it went private amid financial problems. The biotech, founded in 1985 as a spinoff of the Massachusetts Institute of Technology, announced it is merging with a special entity created by Avista Capital, a New York private equity firm. (Saltzman, 8/20)

Stat: Esperion Therapeutics And The Cholesterol Trial That Could Swing Billions

Is a small company poised to shake up the multibillion-dollar market for cardiovascular drugs, or is it about to descend into irrelevance? That’s the question hanging over Esperion Therapeutics and its experimental cholesterol-cutting therapy. The drug is being developed as an option for patients who can’t get what they need from cheap, generic statins but who also don’t require pricey injectable medicines called PCSK9 inhibitors, which can cost more than $10,000 a year. (Garde, 8/21)

The Star Tribune: Blue Cross Affiliate Stella Development Invests In Startups 

A development company that's owned by the corporate parent for Blue Cross and Blue Shield of Minnesota has made two investments this year in health care startups, including a deal announced this month to back a sports medicine company based in Georgia. Stella Development, the Blue Cross affiliate, did not announce financial terms for either deal. (Snowbeck, 8/20)

The Associated Press: AbbVie Donates $100M To Ronald McDonald House Charities

Drugmaker AbbVie is donating $100 million to Ronald McDonald House Charities, which help provide housing to pediatric patients and their families throughout the U.S. The donation announced Monday is the single largest ever gift to Chicago-based charity network. The money will be used to build housing in at least 26 states and at 32 Ronald McDonald Houses. (8/20)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Thursday, April 30
  • Wednesday, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF